| Composition | Rosuvastatin 10mg Fenofibrate 160mg |
|---|---|
| Dosage | TABLET |
| Packing Size | 10×10 |
| Packing | Alu-Alu |
ROZVIN F 10/160 is a combination lipid-lowering therapy that combines Rosuvastatin 10 mg, a potent statin, with Fenofibrate 160 mg, a fibrate derivative. This dual-action formulation is designed to manage mixed dyslipidemia effectively, helping to reduce LDL cholesterol and triglycerides while raising HDL cholesterol.
ROZVIN F 10/160 is suitable for patients who require moderate lipid control, especially those with mixed dyslipidemia or partial response to monotherapy, offering comprehensive lipid management in a single tablet.
Each tablet contains:
Rosuvastatin 10 mg – HMG-CoA reductase inhibitor that lowers LDL cholesterol, total cholesterol, and triglycerides while increasing HDL cholesterol.
Fenofibrate 160 mg – Activates peroxisome proliferator-activated receptor alpha (PPAR-α), reducing triglycerides and VLDL levels while improving HDL cholesterol.
(Excipients q.s., as per approved formulation.)
Tablet
Lipid-Lowering Combination Therapy / Statin + Fibrate
ROZVIN F 10/160 Tablets are indicated for:
Mixed dyslipidemia (elevated LDL and triglycerides)
Patients with hypercholesterolemia inadequately controlled by monotherapy
Prevention of cardiovascular events in high-risk patients
Adjunct therapy to diet and lifestyle modifications for comprehensive lipid management
Rosuvastatin inhibits the HMG-CoA reductase enzyme, reducing cholesterol synthesis in the liver and improving LDL/HDL balance.
Fenofibrate activates PPAR-α, enhancing lipid metabolism, reducing triglycerides and VLDL, and increasing HDL cholesterol.
The combination provides synergistic effects, offering enhanced control of multiple lipid parameters for better cardiovascular protection.
Recommended Dose: As prescribed by the physician, usually once daily
Route: Oral
Duration: Long-term therapy as advised by a healthcare provider
Note: Regular monitoring of lipid profile, liver function, and renal function is recommended during therapy.
Reduces LDL cholesterol and triglycerides
Increases HDL cholesterol
Helps prevent atherosclerosis, heart attack, and stroke
Suitable for patients with mixed dyslipidemia or moderate cardiovascular risk
Convenient once-daily tablet improves adherence
ROZVIN F 10/160 is generally well tolerated. Possible side effects include:
Mild gastrointestinal discomfort (nausea, abdominal pain)
Headache or dizziness
Muscle pain or weakness (rare, associated with statins)
Liver enzyme elevation (rare)
Patients should consult their physician if side effects persist.
Avoid in patients with active liver disease or severe renal impairment
Not recommended during pregnancy or lactation
Inform your doctor about other medications to prevent interactions
Regular monitoring of liver and kidney function is advised during therapy
Store below 25°C, in a dry place away from sunlight. Keep out of reach of children.
Brand Name: ROZVIN F 10/160
Composition: Rosuvastatin 10 mg + Fenofibrate 160 mg
Dosage Form: Tablet
Therapeutic Class: Lipid-Lowering Combination Therapy / Statin + Fibrate
Manufacturer: [Insert Company Name]
Packaging: [Example: 10×10 Tablets / Strip]
Combines statin and fibrate therapy for enhanced lipid control
Provides comprehensive management of mixed dyslipidemia
Convenient once-daily dosing improves compliance
Manufactured under strict GMP-certified quality standards
ROZVIN F 10/160 (Rosuvastatin 10 mg + Fenofibrate 160 mg Tablets) provides dual lipid-lowering therapy for patients with mixed dyslipidemia or moderate cardiovascular risk. By reducing LDL and triglycerides while increasing HDL cholesterol, it supports heart health, prevents atherosclerosis, and reduces the risk of cardiovascular events, providing effective long-term lipid management.
